Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
-
REGULATORY SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
-
REGULATORY Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
-
REGULATORY Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
-
COMMENTARY Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
-
REGULATORY Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
-
BUSINESS Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
-
BUSINESS Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
-
REGULATORY Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
-
BUSINESS Shionogi’s COVID Pill Might Not Be Recommended for Pregnant Women over Birth Defect Risk
April 13, 2022
-
REGULATORY Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
-
REGULATORY Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
-
BUSINESS Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
-
REGULATORY MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
-
BUSINESS New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
-
BUSINESS Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
-
BUSINESS Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
-
BUSINESS Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
-
REGULATORY SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
-
ORGANIZATION JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…